Back to the drug test guide

Oxycodone Test Evidence

Has Caused a False Positive

Naloxone

2 sources Jenkins et al., Clin Chem 2009 Gall and El-Khoury, Clin Chem 2019

What It Found

  • Naloxone can cross-react with certain oxycodone tests, including during investigation of samples from people receiving buprenorphine/naloxone.

Test Studied

  • Selected oxycodone-specific urine immunoassays

Source Smid et al., O G Open 2026

Keep in Mind

  • This is distinct from detecting the shared metabolite noroxymorphone on targeted mass spectrometry.

All 3 sources Jenkins et al., Clin Chem 2009 Gall and El-Khoury, Clin Chem 2019 Smid et al., O G Open 2026

Keep in Mind

  • The formulation alone cannot account for every positive.
  • Suboxone contains both naloxone and buprenorphine.

Naltrexone

2 sources Beauregard and Maguire, Ment Health Clin 2024 Majumdar and Chatterjee, Asian J Psychiatr 2024

What It Found

  • Oral naltrexone was associated with repeated unexpected oxycodone screens.

Test Studied

  • Oxycodone-specific urine immunoassays

2 sources Beauregard and Maguire, Ment Health Clin 2024 Stanciu and Gnanasegaram, J Psychoactive Drugs 2020

What It Found

  • Detailed testing identified noroxymorphone, a minor naltrexone metabolite also formed downstream from oxycodone.

Keep in Mind

  • An isolated shared metabolite should be interpreted alongside the parent compounds and the full medication history.

Test Studied

  • Follow-up drug/metabolite testing

Depends on the Brand of Test

Codeine

Source Haller et al., J Anal Toxicol 2006

What It Found

  • The authors found no DRI interference from Codeine.
  • Codeine or hydrocodone was present in most specimens with a false-positive or indeterminate Monitect POC result.

Keep in Mind

  • The POC observation did not isolate the causal drug.
  • It should not be used to attribute an individual patient result to Codeine.

Test Studied

  • Microgenics DRI on Bayer ADVIA 1650 and Branan Monitect POC, 100 ng/mL oxycodone cutoff

Source Backer et al., J Anal Toxicol 2005

What It Found

  • Patient urine with Codeine above 75,000 ng/mL could remain negative on this oxycodone-specific assay.

Keep in Mind

  • A negative comparator is specific to the DRI assay.
  • A general opiates screen targets different compounds.

Test Studied

  • DRI Oxycodone enzyme immunoassay, 100 ng/mL cutoff, with GC-MS

Hydrocodone

Source Haller et al., J Anal Toxicol 2006

What It Found

  • The authors found no DRI interference from Hydrocodone.
  • Codeine or hydrocodone was present in most specimens with a false-positive or indeterminate Monitect POC result.

Keep in Mind

  • The POC observation did not isolate the causal drug.
  • It should not be used to attribute an individual patient result to Hydrocodone.

Test Studied

  • Microgenics DRI on Bayer ADVIA 1650 and Branan Monitect POC, 100 ng/mL oxycodone cutoff

Source Backer et al., J Anal Toxicol 2005

What It Found

  • Patient urine with Hydrocodone above 75,000 ng/mL could remain negative on this oxycodone-specific assay.

Keep in Mind

  • A negative comparator is specific to the DRI assay.
  • A general opiates screen targets different compounds.

Test Studied

  • DRI Oxycodone enzyme immunoassay, 100 ng/mL cutoff, with GC-MS

The Test Is Made to Find It

Oxycodone

2 sources Gingras et al., J Anal Toxicol 2010 Stolbach et al., J Med Toxicol 2022

What It Found

  • Oxycodone and its metabolite oxymorphone are targets of commonly used dedicated oxycodone screens.

Keep in Mind

  • The presence of the prescribed drug is analytically expected.

Source Haller et al., J Anal Toxicol 2006

What It Found

  • Two oxycodone screen-positive urines containing less than 50 ng/mL free oxycodone contained oxymorphone and oxycodone glucuronide above 100 ng/mL.

Keep in Mind

  • Confirmation must cover appropriate metabolites when free parent drug has decreased.

Source Heltsley et al., J Anal Toxicol 2010

What It Found

  • Urines containing only noroxycodone were best detected by the oxycodone EIA in this pain-clinic comparison.

Keep in Mind

  • Noroxycodone is an actual oxycodone metabolite.
  • Other platforms can respond differently.

Test Studied

  • Oxycodone urine ELISA and EIA compared with LC-MS/MS

Source Stolbach et al., J Med Toxicol 2022

Keep in Mind

  • Urine concentration alone cannot identify dose or impairment.

3 sources Gingras et al., J Anal Toxicol 2010 Stolbach et al., J Med Toxicol 2022 Haller et al., J Anal Toxicol 2006

Test Studied

  • Oxycodone-specific urine immunoassay and GC-MS

2 sources Gingras et al., J Anal Toxicol 2010 Haller et al., J Anal Toxicol 2006

Test Studied

  • Microgenics DRI oxycodone and GC-MS confirmation

Suspected, but Not Proven

Hydroxychloroquine

Source Radke et al., Toxicol Rep 2019

What It Found

  • After a large overdose, the urine sample caused an absorbance alarm on the oxycodone screen.
  • Spiking showed that high levels could affect several urine assays.

Keep in Mind

  • An instrument alarm is an uninterpretable result, not a demonstrated positive oxycodone screen.

Test Studied

  • Enzyme immunoassay for oxycodone

Tested: No False Positive Found

Hydromorphone

Source Haller et al., J Anal Toxicol 2006

What It Found

  • The authors found no DRI oxycodone interference from Hydromorphone.

Keep in Mind

  • The result applies to the tested DRI method.
  • The abstract does not specify a comparator spike concentration.

Test Studied

  • Microgenics DRI oxycodone test on a Bayer ADVIA 1650, cutoff 100 ng/mL

Source Backer et al., J Anal Toxicol 2005

What It Found

  • Patient urine with Hydromorphone above 12,000 ng/mL could remain negative on this oxycodone-specific assay.

Keep in Mind

  • A negative comparator is specific to the DRI assay.
  • A general opiates screen targets different compounds.

Test Studied

  • DRI Oxycodone enzyme immunoassay, 100 ng/mL cutoff, with GC-MS

Morphine

Source Haller et al., J Anal Toxicol 2006

What It Found

  • The authors found no DRI oxycodone interference from Morphine.

Keep in Mind

  • The result applies to the tested DRI method.
  • The abstract does not specify a comparator spike concentration.

Test Studied

  • Microgenics DRI oxycodone test on a Bayer ADVIA 1650, cutoff 100 ng/mL

Source Backer et al., J Anal Toxicol 2005

What It Found

  • Patient urine with Morphine above 163,000 ng/mL could remain negative on this oxycodone-specific assay.

Keep in Mind

  • A negative comparator is specific to the DRI assay.
  • A general opiates screen targets different compounds.

Test Studied

  • DRI Oxycodone enzyme immunoassay, 100 ng/mL cutoff, with GC-MS

Acetaminophen

Source Lin et al., J Anal Toxicol 2013

What It Found

  • The authors observed no interference from Acetaminophen at 1,000 ng/mL when it was added to drug-free urine for the cup comparison.

Keep in Mind

  • This is a single challenge level.
  • It cannot rule out interference at a higher concentration or with a different device.

Test Studied

  • NexScreen and DrugCheck Waive RT cups, as applicable to their respective panels

Dextromethorphan

Source Lin et al., J Anal Toxicol 2013

What It Found

  • The authors observed no interference from Dextromethorphan at 1,000 ng/mL when it was added to drug-free urine for the cup comparison.

Keep in Mind

  • This is a single challenge level.
  • It cannot rule out interference at a higher concentration or with a different device.

Test Studied

  • NexScreen and DrugCheck Waive RT cups, as applicable to their respective panels

Dihydrocodeine

Source Haller et al., J Anal Toxicol 2006

What It Found

  • The authors found no DRI oxycodone interference from Dihydrocodeine.

Keep in Mind

  • The result applies to the tested DRI method.
  • The abstract does not specify a comparator spike concentration.

Test Studied

  • Microgenics DRI oxycodone test on a Bayer ADVIA 1650, cutoff 100 ng/mL

Diphenhydramine

Source Lin et al., J Anal Toxicol 2013

What It Found

  • The authors observed no interference from Diphenhydramine at 1,000 ng/mL when it was added to drug-free urine for the cup comparison.

Keep in Mind

  • This is a single challenge level.
  • It cannot rule out interference at a higher concentration or with a different device.

Test Studied

  • NexScreen and DrugCheck Waive RT cups, as applicable to their respective panels

Heroin

Source Haller et al., J Anal Toxicol 2006

What It Found

  • The authors found no DRI oxycodone interference from 6-monoacetylmorphine, the heroin metabolite.

Keep in Mind

  • Only the heroin metabolite 6-acetylmorphine (6-MAM) was tested.
  • The experiment gives no direct result for the parent drug.
  • The abstract does not give the challenge concentration.

Test Studied

  • Microgenics DRI oxycodone test on a Bayer ADVIA 1650, cutoff 100 ng/mL

Levofloxacin

Source Colby et al., Clin Biochem 2019

What It Found

  • Levofloxacin did not cross-react with the oxycodone assay in the same study in which it reacted with the morphine-class opiate and buprenorphine reagents.

Keep in Mind

  • The negative finding is specific to the assay and concentrations studied.

Test Studied

  • Abbott MULTIGENT oxycodone

Meprobamate

Source Lin et al., J Anal Toxicol 2013

What It Found

  • The authors observed no interference from Meprobamate at 1,000 ng/mL when it was added to drug-free urine for the cup comparison.

Keep in Mind

  • This is a single challenge level.
  • It cannot rule out interference at a higher concentration or with a different device.

Test Studied

  • NexScreen and DrugCheck Waive RT cups, as applicable to their respective panels